DOCSLIB.ORG

Uterine Atony Is Failure of the Uterus to Contract Following Delivery and Is a Common Cause of Postpartum Hemorrhage

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Uterine Atony Is Failure of the Uterus to Contract Following Delivery and Is a Common Cause of Postpartum Hemorrhage Uterine atony is failure of the uterus to contract following delivery and is a common cause of postpartum hemorrhage. The options for treating hemorrhage due to this cause are uterotonic agents, including additional oxytocin, carboprost tromethamine, methylergonovine, and misoprostol. Prioritizing the optimal therapy given the circumstances is imperative to maternal safety. ILLUSTRATION: JOE GORMAN FOR OBG MANAGEMENT ILLUSTRATION: 8 OBG Management | July 2016 | Vol. 28 No. 7 obgmanagement.com Editorial Stop using rectal misoprostol for the treatment of postpartum hemorrhage caused by uterine atony For women who experience a postpartum hemorrhage, and already have received oxytocin as part of routine obstetric care, prioritize the use of parenteral uterotonics, including oxytocin, methylergonovine, and carboprost tromethamine, and avoid the use of rectal misoprostol Robert L. Barbieri, MD Editor in Chief, OBG MANAGEMENT Chair, Obstetrics and Gynecology Brigham and Women’s Hospital, Boston, Massachusetts Kate Macy Ladd Professor of Obstetrics, Gynecology and Reproductive Biology Harvard Medical School, Boston ost authorities recommend clinical trials and pharmacokinetic 89%, respectively). Fewer women had that, following delivery, studies suggest that rectal misoprostol blood loss of 1,000 mL or greater when Mall women should receive is not an optimal choice if parenteral treated with oxytocin compared with a uterotonic medication to reduce uterotonics are available. Here I pre- misoprostol (1% vs 3%, respectively; the risk of postpartum hemorrhage sent this evidence and urge you to P = .062). In addition, oxytocin was (PPH).1 In the United States, the pre- stop the practice of using rectal miso- associated with fewer temperature ferred uterotonic for this preventive prostol in efforts to manage PPH. elevations of 38°C (100.4°F) or above effort is oxytocin—a low-cost, highly (15% vs 22% for misoprostol, P = .007) effective agent that typically is admin- and fewer temperature elevations of istered as an intravenous (IV) infu- RCTs do not support the 40°C (104°F) or above (0.2% vs 1.2% sion or intramuscular (IM) injection. use of rectal misoprostol for misoprostol, P = .11). Unfortunately, even with the univer- Randomized clinical trials (RCTs) In another trial, women with a sal administration of oxytocin in the have not demonstrated that miso- vaginal delivery who were not treated third stage of labor, PPH occurs in prostol is superior to oxytocin for the with a uterotonic in the third stage about 3% of vaginal deliveries. treatment of PPH caused by uterine were monitored for the develop- A key decision in treating a PPH atony.2 For example, Blum and col- ment of a PPH.4 PPH did develop in due to uterine atony is treatment with leagues studied 31,055 women who 1,422 women, who were then ran- an optimal uterotonic. The options received oxytocin (by IV or IM route) domly assigned to receive oxytocin include: at vaginal delivery and observed (10 U IV or IM) plus a placebo tablet 1. additional oxytocin that 809 (3%) developed a PPH.3 The or oxytocin plus misoprostol (600 µg 2. carboprost tromethamine women who developed PPH were sublingual). (Hemabate) randomly assigned to treatment with Comparing oxytocin alone ver- 3. methylergonovine (Methergine) misoprostol 800 µg sublingual or oxy- sus oxytocin plus misoprostol, there 4. misoprostol. tocin 40 U in 1,000 mL as an IV infu- was no difference in blood loss of Many obstetricians choose rectal sion over 15 minutes. 500 mL or greater after treatment initi- misoprostol alone or in combination Both oxytocin and misoprostol ation (14% vs 14%). However, 90 min- with oxytocin as the preferred treat- had similar efficacy for controlling utes following treatment, temperature ment of PPH. However, evidence from bleeding within 20 minutes (90% and elevations occurred much more often obgmanagement.com Vol. 28 No. 7 | July 2016 | OBG Management 9 Editorial serum concentrations, longer time TABLE Peak circulating concentration of misoprostol (pg/mL) following various routes of administration to onset of uterine contraction, and less contractility than buccal admin- Khan Khan Meckstroth istration. The one advantage of rectal 6 7 8 Study (2003) (2004) (2006) administration is that it has a longer Dose of misoprostol 600 µg 400 µg 400 µg duration of action than the oral, buc- cal, or sublingual routes. In phar- Route of administration macokinetic comparisons of buccal Oral 327 254 − versus sublingual administration of Buccal − − 265 misoprostol, the sublingual route results in greater peak concentra- Vaginal − 211 446 tion, which may cause more adverse 9,10 Rectal 184 87 202 effects. in the women who received oxytocin resulted in higher peak uterine tone Prioritize oxytocin, plus misoprostol compared with the than rectal administration (49 vs methergine, and women who received oxytocin alone 31 mm Hg).8 In addition, time to carboprost tromethamine (temperature ≥38°C: 58% vs 19%; onset of uterine contractility was When treating PPH, administration of temperature ≥40°C: 6.8% vs 0.4%). 41 minutes and 103 minutes, oxytocin, methylergonovine, or carbo- Bottom line: If you have access to respectively, for buccal and rectal prost tromethamine rapidly provides oxytocin, there is no advantage to administration. therapeutic concentration of medica- using misoprostol to treat a PPH due These studies show that rectal tion. For oxytocin, 40 U in 1 L, admin- to uterine atony.5 misoprostol is associated with lower istered at a rate sufficient to control Rectal misoprostol does Misoprostol is a useful uterotonic if parenteral agents not achieve optimal are not available circulating concentrations of the drug Worldwide, approximately one maternal death occurs every 7 minutes. Post- Misoprostol tablets are formulated partum hemorrhage (PPH) is a common cause of maternal death. Oxytocin, for oral administration, not rectal methylergonovine, and carboprost tromethamine should be stored in a refrig- administration. The studies in the erated environment to ensure the stability and bioavailability of the drug. In settings in which reliable refrigeration is not available, misoprostol, a medica- TABLE show that rectal administra- tion that is heat-stable, is often used to prevent and treat PPH. tion of misoprostol results in lower One approach to preventing PPH is to provide 600 µg of misoprostol to circulating concentration of the women delivering at home without a skilled birth attendant that they can self- medication compared to oral, buc- administer after the delivery.1,2 Another approach is to recommend that skilled cal, or vaginal administration.6−8 After birth attendants administer misoprostol following the delivery.3 Although I am recommending that we not use rectal misoprostol to treat PPH rectal administration it takes about in the United States, it is clear that misoprostol plays an important role in prevent- 60 minutes to reach the peak circulat- ing PPH in countries where parenteral uterotonics are not available. If a clinician in ing concentration of misoprostol.6,7 the United States was involved in a home birth complicated by PPH due to uterine By contrast, parenteral oxytocin, atony, and if misoprostol was the only available uterotonic, it would be wise to methylergonovine, and carboprost administer it promptly. tromethamine reach peak serum References concentration much more quickly 1. Rajbhandari S, Hodgins S, Sanghvi H, McPherson R, Pradhan YV, Baqui AH; Misoprostol Study Group. Expanding uterotonic protection following childbirth through community-based distribution of misopros- after administration. tol: operations research study in Nepal. Int J Gynaecol Obstet. 2010;108(3):282−288. In a study of misoprostol stim- 2. Sanghvi H, Ansari N, Prata NJ, Gibson H, Ehsan AT, Smith JM. Prevention of postpartum hemorrhage at home ulation of uterine contractility as birth in Afghanistan. Int J Gynaecol Obstet. 2010;108(3):276−281. 3. Prata N, Mbaruku G, Campbell M, Potts M, Vahidnia F. Controlling postpartum hemorrhage after home measured by an intrauterine pres- births in Tanzania. Int J Gynaecol Obstet. 2005;90(1):51−55. sure catheter, buccal administration CONTINUED ON PAGE 12 10 OBG Management | July 2016 | Vol. 28 No. 7 obgmanagement.com Editorial CONTINUED FROM PAGE 10 atony, or 10 U IM injection are often There is scant evidence that effective in controlling bleeding due misoprostol is more effective than to atony. Carboprost tromethamine oxytocin, and misoprostol clearly 0.25 mg administered intramuscularly causes a higher rate of elevated tem- every 15 minutes up to 8 doses pro- perature than any of the parenteral vides an excellent second-line agent. uterotonic agents. In your practice Carboprost tromethamine is contrain- stop using rectal misoprostol for the dicated for women with asthma. treatment of PPH caused by uterine Could you answer Methylergonovine 0.2 mg atony, and prioritize the use of paren- posttest questions administered intramuscularly only teral uterotonics. can be given every 2 to 4 hours. Con- on this editorial? sequently, because time is of the Find out! To test yourself, visit essence in managing a severe PPH, obgmanagement.com it is unusual to be able to administer /md-iq-quizzes. more than one dose of the agent dur- [email protected] Free registration required. ing the course of treatment. Methy- lergonovine is contraindicated for Dr. Barbieri reports no financial women with hypertension. relationships relevant to this article. References 1. Westhoff G, Cotter AM, Tolosa JE. Prophylactic as an adjunct to standard uterotonics for treat- 8. Meckstroth KR, Whitaker AK, Bertisch S, Gold- oxytocin for the third stage of labour to prevent ment of post-partum haemorrhage: a multi- berg AB, Darney PD. Misoprostol administered postpartum hemorrhage. Cochrane Database centre, double-blind randomised trial. Lancet. by epithelial routes: drug absorption and uter- Syst Rev. 2013;(10):CD001808. 2010;375(9728):1808−1813. ine response. Obstet Gynecol. 2006;108(3 pt 2. Gibbons KJ, Albright CM, Rouse DJ. Postpar- 5. Weeks A. The prevention and treatment of post- 1):582−590. tum hemorrhage in the developed world: partum hemorrhage: what do we know and where 9.
Load more

Recommended publications
  • Case 1: Postpartum Hemorrhage Secondary to Uterine Atony
    Case 1: Postpartum Hemorrhage Secondary to Uterine Atony Learning Objectives By the end of this scenario, each care team member should be able to successfully do the following: ▪ Recognize risk factors for postpartum hemorrhage. ▪ Identify postpartum hemorrhage due to uterine atony and be able to treat with appropriate medical management. ▪ Demonstrate teamwork and communication skills during a simulated postpartum hemorrhage. Planned Completion Points To successfully complete this scenario, the care team should successfully do the following: ▪ Recognize uterine atony as the etiology for postpartum hemorrhage. ▪ Perform uterine massage. ▪ Administer two different uterotonic medications. ▪ Call for blood (e.g. 2 units of PRBCs). OR Page | 1 © 2019 American College of Obstetricians and Gynecologists ▪ If 10 minutes has elapsed after recognition of hemorrhage and the team has not corrected the hemorrhage or called for blood. Expected Duration Approximately 60 minutes (30 minutes for simulation / 30 minutes for debriefing). Case Scenario Patient: Marla Smith Mrs. Marla Smith is a 38-year-old G3P2012 who was admitted in active labor at 39+3 weeks and had a spontaneous vaginal delivery 30 minutes ago. Her delivery was uncomplicated. She had a first-degree laceration that did not require repair. She is approximately 30 minutes postpartum and has just called out because she feels dizzy and has more bleeding. Patient Information ▪ She has no significant past medical history. ▪ She has no known drug allergies. ▪ Her pregnancy was uncomplicated except for an elevated 1-hour glucose screen with a normal 3- hour glucose tolerance test. Laboratory Data (On Admission): ▪ Hemoglobin: 12.2 ▪ Hematocrit: 36.6 ▪ WBC: 12,000 ▪ Platelets: 218,000 Delivery Information ▪ Measurement of cumulative blood loss (as quantitative as possible) from the delivery was 300cc.
    [Show full text]
  • E001466.Full.Pdf
    Editorial BMJ Glob Health: first published as 10.1136/bmjgh-2019-001466 on 11 April 2019. Downloaded from WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? Joshua P Vogel, 1,2 Myfanwy Williams,3 Ioannis Gallos,4 Fernando Althabe,1 Olufemi T Oladapo1 To cite: Vogel JP, THE GLOBAL BURDEN OF POSTPARTUM trials of tranexamic acid for PPH treatment Williams M, Gallos I, et al. HAEMORRHAGE and a heat-stable formulation of carbetocin WHO recommendations on 6–12 uterotonics for postpartum Obstetric haemorrhage, especially post- for PPH prevention. The increasing haemorrhage prevention: partum haemorrhage (PPH), was responsible number of PPH prevention and management what works, and which for more than a quarter of the estimated 303 options makes it challenging for providers one?BMJ Glob Health 000 maternal deaths that occurred globally in and health system stakeholders to choose 2019;4:e001466. doi:10.1136/ 2015.1 PPH—commonly defined as a blood where and how to invest limited resources in bmjgh-2019-001466 loss of 500 mL or more within 24 hours after order to optimise health outcomes. birth—affects about 6% of all women giving Multiple uterotonics have been eval- Handling editor Seye Abimbola birth.1 Uterine atony is the most common uated for PPH prevention over the past Received 4 February 2019 cause of PPH, but it can also be caused by four decades, including oxytocin receptor Revised 10 March 2019 genital tract trauma, retained placental tissue agonists (oxytocin and carbetocin), prosta- Accepted 16 March 2019 or maternal bleeding disorders. The majority glandin analogues (misoprostol, sulprostone, of women who experience PPH have no iden- carboprost), ergot alkaloids (such as ergo- tifiable risk factor, meaning that PPH preven- metrine/methylergometrine) and combina- tion programmes rely on universal use of PPH tions of these (oxytocin plus ergometrine, © Author(s) (or their prophylaxis for all women in the immediate or oxytocin plus misoprostol).
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME PROSTIN 15M 250 microgram (µg)/mL Solution for Injection 2. QUALITATIVE AND QUANTITIATIVE COMPOSITION Each 1 mL contains 250 μg carboprost or 332 μg carboprost (as tromethamine). Excipient(s) with known effect Each 1 mL contains 9.45 mg/mL benzyl alcohol (added as preservative). For the full list of excipients, see section 6.1. 3. PHARMACEUTIAL FORM Solution for Injection. PROSTIN 15M is a clear colourless solution. 4. CLINCAL PARTICUALRS 4.1 Therapeutic indications PROSTIN 15M is indicated for the treatment of postpartum haemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of PROSTIN 15M has resulted in satisfactory control of haemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered embolic agents have contributed to the outcome. In a high proportion of cases, PROSTIN 15M used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention. 4.2 Dose and method of administration Dose An initial dose of 250 µg (1 mL) is to be given by deep intramuscular injection. In clinical trials, it was found that the majority of successful cases (73%) responded to single injections. In some selected cases, however, multiple dosing at intervals of 15 to 90 minutes was carried out with successful outcome. The need for additional injections and the interval at which these should be given can be determined only by the attending physicians as dictated by the course of clinical events.
    [Show full text]
  • Mid Trimester Termination; Pgf2 Alpha Versus Misoprostol
    MID TRIMESTER TERMINATION The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-2497 MID TRIMESTER TERMINATION; PGF2 ALPHA VERSUS MISOPROSTOL Dr. Ghazala Niaz1, Dr. Rubina Ali2, Dr. Shazia Shaheen3 1. MCPS, FCPS Senior Registrar Gynae Unit-II ABSTRACT… Objective: The objective of study was to compare the efficacy of extra amniotic DHQ Hospital, Faisalabad prostaglandin F2 alpha and vaginal misoprostol for termination of 2nd trimester pregnancy. 2. MCPS, FCPS Study design: It was quasi experimental study. Place and duration of study: The study was Professor Gynae Unit-II DHQ Hospital, Faisalabad conducted at Gynae Unit II, DHQ Hospital affiliated with Punjab Medical College, Faisalabad for 3. FCPS a period of one year from July 2012 to June 2013. Material and methods: This study included Assistant Professor Gynae Unit-II 100 patients who presented with congenitally anomalous foetus or IUD during 2nd trimester for DHQ Hospital, Faisalabad termination of pregnancy. Outcome was evaluated by percentage of successful cases for TOP Correspondence Address: and induction to delivery interval. Result: As regards the efficacy of misoprostol, success rate Dr. Ghazala Niaz for termination of pregnancy was 86% and mean induction to delivery interval was 13.16±1.987 Senior Registrar Gynae Unit-II hours. Regarding PGF alpha success rate for TOP was 88% and mean induction to delivery DHQ Hospital, Faisalabad 2 [email protected] interval was 16.07±3.202 hours. Conclusions: Misoprostol is comparable in its efficacy to PGF2 alpha for mid trimester termination and can be used as a cheaper alternative. Article received on: 17/04/2014 Key words: Misoprostol, Mid trimester termination, Prostaglandin F2 alpha.
    [Show full text]
  • Eicosanoids & Platelet Activating Factor
    Eicosanoids & Platelet Activating Factor Prof. Sanjay Khattri Dept. of Pharmacology & Therapeutics King George’s Medical University, Lucknow 1 Autacoid These are the substances produced by wide variety of cells that act locally at the site of production. (local hormones) 2 Mediators of Inflammation and Immune reaction 1. Vasoactive amines (Histamine and Serotonin) 2.Eicosanoids 3.Platlet Activating Factor 4.Bradykinins 4.Nitric Oxide 5.Neuropeptides 6.Cytokinines 3 EICOSANOIDS PGs, TXs and LTs are all derived from eicosa (referring to 20 C atoms) tri/tetra/ penta enoic acids. Therefore, they can be collectively called eicosanoids. Major source: 5,8,11,14 eicosa tetraenoic acid (arachidonic acid). Other eicosanoids of increasing interest are: lipoxins and resolvins. The term prostanoid encompasses both prostaglandins and thromboxanes. 4 EICOSANOIDS Contd…. In most instances, the initial and rate-limiting step in eicosanoid synthesis is the liberation of intracellular arachidonate, usually in a one-step process catalyzed by the enzyme phospholipase A2 (PLA2). PLA2 generates not only arachidonic acid but also lysoglyceryl - phosphorylcholine (lyso-PAF), the precursor of platelet activating factor (PAF). 5 EICOSANOIDS Contd…. Corticosteroids inhibit the enzyme PLA2 by inducing the production of lipocortins (annexins). The free arachidonic acid is metabolised separately (or sometimes jointly) by several pathways, including the following: Cyclo-oxygenase (COX)- Two main isoforms exist, COX-1 and COX-2 Lipoxygenases- Several subtypes, which
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH HEMABATE® STERILE SOLUTION (carboprost tromethamine injection USP) 250 µg/mL Prostaglandin Pfizer Canada Inc. Date of Revision: 17,300 Trans-Canada Highway February 21, 2014 Kirkland, Quebec H9J 2M5 Control No. 170114 ® Pfizer Enterprises SARL Pfizer Canada Inc, Licensee © Pfizer Canada Inc. 2014 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY OF PRODUCT INFORMATION ..................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION ..............................................................................11 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................12 DOSAGE
    [Show full text]
  • Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins
    Article Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins Márton Enesei 1,2,László Takács 2, Enik˝oTormási 3, Adrienn Tóthné Rácz 3, Zita Róka 3, Mihály Kádár 3 and Zsuzsanna Kardos 2,* 1 Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, M˝uegyetemrakpart 3, 1111 Budapest, Hungary; [email protected] 2 CHINOIN, a member of Sanofi Group, PG Development, Tó utca 1-5, 1045 Budapest, Hungary; laszlo.takacs@sanofi.com 3 CHINOIN, a member of Sanofi Group, PG Analytics, Tó utca 1-5, 1045 Budapest, Hungary; robertne.tormasi@sanofi.com (E.T.); adrienn.tothneracz@sanofi.com (A.T.R.); zita.roka@sanofi.com (Z.R.); mihaly.kadar@sanofi.com (M.K.) * Correspondence: zsuzsanna.kardos@sanofi.com Received: 15 June 2020; Accepted: 10 August 2020; Published: 18 August 2020 Abstract: Four enantiomeric forms of natural prostaglandins, ent-PGF α (( )-1), ent-PGE ((+)-2) 2 − 2 ent-PGF α (( )-3), and ent-PGE ((+)-4) have been synthetized in gram scale by Corey synthesis used 1 − 1 in the prostaglandin plants of CHINOIN, Budapest. Chiral HPLC methods have been developed to separate the enantiomeric pairs. Enantiomers of natural prostaglandins can be used as analytical standards to verify the enantiopurity of synthetic prostaglandins, or as biomarkers to study oxidation processes in vivo. Keywords: preparation; ent-PGF2α; ent-PGF1α; ent-PGE2; ent-PGE1; chiral HPLC; enantiomeric separation; mirror images; enantiopurity 1. Introduction Interest in the field of prostaglandins has been steadily growing since the basic work of Bergström Samuelsson, and Vane [1–3]. Their discoveries revealed the structure, the enzyme-controlled biochemical synthesis from arachidonic acid, and the main physiological effects of prostaglandins as well as their related substances.
    [Show full text]
  • A Guide to Obstetrical Coding Production of This Document Is Made Possible by Financial Contributions from Health Canada and Provincial and Territorial Governments
    ICD-10-CA | CCI A Guide to Obstetrical Coding Production of this document is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Unless otherwise indicated, this product uses data provided by Canada’s provinces and territories. All rights reserved. The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited. For permission or information, please contact CIHI: Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca [email protected] © 2018 Canadian Institute for Health Information Cette publication est aussi disponible en français sous le titre Guide de codification des données en obstétrique. Table of contents About CIHI ................................................................................................................................. 6 Chapter 1: Introduction ..............................................................................................................
    [Show full text]
  • Postpartum Haemorrhage
    Guideline Postpartum Haemorrhage Immediate Actions Call for help and escalate as necessary Initiate fundal massage Focus on maternal resuscitation and identifying cause of bleeding Determine if placenta still in situ Tailor pharmacological management to causation and maternal condition (see orange box). Complete a SAS form when using carboprost. Pharmacological regimen (see flow sheet summary) Administer third stage medicines if not already done so. Administer ergometrine 0.25mg both IM and slow IV (contraindicated in hypertension) IF still bleeding: Administer tranexamic acid- 1g IV in 10mL via syringe driver set at 1mL/minute administered over 10 minutes OR as a slow push over 10 minutes. Administer carboprost 250micrograms (1mL) by deep intramuscular injection Administer loperamide 4mg PO to minimise the side-effect of diarrhoea Administer antiemetic ondansetron 4mg IV, if not already given Prophylaxis Once bleeding is controlled, administer misoprostol 600microg buccal and initiate an infusion of oxytocin 40IU in 1L Hartmann’s at a rate of 250mL/hr for 4 hours. Flow chart for management of PPH Carboprost Bakri Balloon Medicines Guide Ongoing postnatal management after a major PPH 1. Purpose This document outlines the guideline details for managing primary postpartum haemorrhage at the Women’s. Where processes differ between campuses, those that refer to the Sandringham campus are differentiated by pink italic text or have the heading Sandringham campus. For guidance on postnatal observations and care after a major PPH, please refer to the procedure ‘Postpartum Haemorrhage - Immediate and On-going Postnatal Care after Major PPH 2. Definitions Primary postpartum haemorrhage (PPH) is traditionally defined as blood loss greater than or equal to 500 mL, within 24 hours of the birth of a baby (1).
    [Show full text]
  • NAF's 2015 Clinical Policy Guidelines
    2015 2015 Clinical Policy Guidelines ©2015 National Abortion Federation 1660 L Street, NW, Suite 450 Washington, DC 20036 www.prochoice.org National Abortion Federation Clinical Policy Guidelines can be accessed on the Internet at www.guidelines.gov. The National Abortion Federation is the professional association of abortion providers. Our mission is to ensure safe, legal, and accessible abortion care, which promotes health and justice for women. National Abortion Federation National Abortion Federation TABLE OF CONTENTS INTRODUCTION ..................................................................................................................iii NOTES ON FORMATTING..................................................................................................... v 1. WHO CAN PROVIDE ABORTIONS ..................................................................................... 1 2. PATIENT EDUCATION,COUNSELING,AND INFORMED CONSENT ......................................... 2 3. INFECTION PREVENTION AND CONTROL ........................................................................... 4 4. LABORATORY PRACTICE ................................................................................................. 8 5. LIMITED SONOGRAPHY IN ABORTION CARE .................................................................... 10 6. EARLY MEDICAL ABORTION........................................................................................... 13 7. FIRST-TRIMESTER SURGICAL ABORTION .......................................................................
    [Show full text]
  • Cord Prolapse
    CLINICAL PRACTICE GUIDELINE CORD PROLAPSE CLINICAL PRACTICE GUIDELINE CORD PROLAPSE Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland and the Clinical Strategy and Programmes Division, Health Service Executive Version: 1.0 Publication date: March 2015 Guideline No: 35 Revision date: March 2017 1 CLINICAL PRACTICE GUIDELINE CORD PROLAPSE Table of Contents 1. Revision History ................................................................................ 3 2. Key Recommendations ....................................................................... 3 3. Purpose and Scope ............................................................................ 3 4. Background and Introduction .............................................................. 4 5. Methodology ..................................................................................... 4 6. Clinical Guidelines on Cord Prolapse…… ................................................ 5 7. Hospital Equipment and Facilities ....................................................... 11 8. References ...................................................................................... 11 9. Implementation Strategy .................................................................. 14 10. Qualifying Statement ....................................................................... 14 11. Appendices ..................................................................................... 15 2 CLINICAL PRACTICE GUIDELINE CORD PROLAPSE 1. Revision History Version No.
    [Show full text]
  • Disruption of Protein-Protein Interactions
    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2016 Supplementary data Disruption of Protein-Protein Interactions: Hot spot detection, structure-based virtual screening and in vitro testing for anti-cancer drug target – Survivin Sailu Sarvagalla,a Chun Hei Antonio Cheung,b,c Ju-Ya Tsai,b Hsing Pang Hsieh,d and Mohane Selvaraj Coumara,* aCentre for Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry 605014, India. bDepartment of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan R.O.C. cInstitute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan R.O.C. dInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan, ROC. * Corresponding author: M.S. Coumar; Phone, +91-413-2654950; fax, +91-413-2655211; e-mail, [email protected] S1 Contents A. Figures....................................................................................................................................S3 B. Tables…………………………………………………………………………………….... S6 S2 a Borealin hot spots per-residue energy decomposition 1 0 -1 l -2 o m -3 / l a c -4 k -5 G Δ -6 -7 -8 -9 Residues b INCENP hot spots per-residue energy decomposition 0 l -0.5 o m -1 / l a c -1.5 k -2 G Δ -2.5 -3 Residues Figure S1. Hot spot residue-wise energy contribution for the complex (a) Borealin hot spot residues energy contribution and (b) INCENP protein hot spot residues energy contribution. S3 Figure S2. Mapping of the energetically important residues in CPC interface region. Hot spots, warm hot spots and null spots are represented in red, gold and light green color, respectively.
    [Show full text]